Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-targeted U-CART
- Development stage
- Preclinical
- Lead developer
- EyeBiotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA-targeted U-CART is an allogeneic, "off-the-shelf" chimeric antigen receptor T-cell (CAR-T) therapy being developed by Fundamenta Biotech Limited, a subsidiary of Fundamenta Therapeutics. The therapy is designed to treat multiple myeloma by targeting the B-cell maturation antigen (BCMA), which is highly expressed on the surface of malignant plasma cells. As a universal CAR-T (U-CART) product, it utilizes T cells derived from healthy donors rather than the patients themselves, which are engineered to prevent graft-versus-host disease (GvHD) and immune rejection. This approach potentially allows for immediate treatment availability and reduced manufacturing costs compared to autologous CAR-T therapies. The drug is currently in the preclinical stage of development.
- Other names
- BCMA-targeted Universal CAR-T cell therapyBCMA-targeted U-CART-Fundamenta Biotech Limited-BCMA-Universal CAR-T cell therapy-cell therapy-Multiple Myeloma
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA-targeted U-CART.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-targeted U-CART.